Vantage Isotopes Revenue Share

A share of metered output from an operating actinium-225 and molybdenum-99 production line.

Actinium-225 is one of the scarcest useful substances on earth and targeted alpha therapy demand is growing faster than supply. Vantage operates an accelerator-driven subcritical target that has been shipping for two years under three take-or-pay distribution agreements. Investors receive 4% of gross isotope revenue until a 1.9x cap, paid quarterly against metered output.

Discovery Ridge Research Park · Columbia, MOIn commercial operationEscrow: Cadence Escrow Services

TRL 9 of 9, band 8.8 to 9, signed by Dr. Samuel Adeyemi, PhD Nuclear Engineering; ASME Section III reviewer, on May 15, 2026.See the evidence it rests on

$5,000,000 committed of $5,000,000

$5,000,000 released · 100% subscribed

Released to the issuerCommitted, held in escrowRemaining

Minimum: $100
Instrument: Revenue share
Term: 10 yr
Investors: 2,766

Closed April 30, 2026

Eligibility depends on residency, accreditation status and how much you have already invested this year.
You can read everything about this offering without an account. Committing capital requires one.

Open an account

Open an account to invest

Demo · viewing as

Browsing without an account. Everything is visible; nothing is purchasable until you verify who and where you are.

Or answer the questions yourself

No money will move

No payment processor is connected. The commitment flow runs end to end, through amount, agreement, signature and receipt, and records a simulated position rather than a charge.

Issuer updates

Second target station procurement underway
May 20, 2026
With the revenue share fully committed and released, procurement for the second target station has begun. Contracted volume already exceeds what the first station can produce, which is the reason for the expansion.
Sofia Marchetti, CEO

Vantage Isotopes Revenue Share

Issuer updates

Second target station procurement underway